

James L Gulley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5539410/publications.pdf>

Version: 2024-02-01

486
papers

20,973
citations

11608

70
h-index

16127

124
g-index

496
all docs

496
docs citations

496
times ranked

19663
citing authors

#	ARTICLE	IF	CITATIONS
1	Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1099-1105.	0.8	900
2	Androgen Deprivation Therapy for Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 238.	3.8	880
3	Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, in Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2117-2124.	0.8	538
4	Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2018, 19, 51-64.	5.1	491
5	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 1148-1157.	1.6	391
6	Cancer Vaccines: Moving Beyond Current Paradigms. <i>Clinical Cancer Research</i> , 2007, 13, 3776-3782.	3.2	367
7	Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 3353-3362.	3.2	357
8	Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. <i>Lancet Oncology</i> , The, 2012, 13, 501-508.	5.1	333
9	Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 2532-2539.	0.8	316
10	Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF β 2, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 1287-1295.	3.2	304
11	Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer. <i>JAMA Oncology</i> , 2019, 5, 393.	3.4	303
12	Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen-Expressing Carcinomas. <i>Journal of Clinical Oncology</i> , 2005, 23, 720-731.	0.8	290
13	A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. <i>Clinical Cancer Research</i> , 2006, 12, 1260-1269.	3.2	286
14	Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 663-674.	2.0	279
15	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. <i>Lancet Oncology</i> , The, 2017, 18, 587-598.	5.1	261
16	Current Landscape of Immunotherapy in Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1205.	3.4	260
17	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2017, 18, 599-610.	5.1	257
18	Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy. <i>Clinical Cancer Research</i> , 2011, 17, 907-917.	3.2	224

#	ARTICLE	IF	CITATIONS
19	Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. <i>Prostate</i> , 2002, 53, 109-117.	1.2	220
20	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. , 2018, 6, 141.		214
21	Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 3060-3069.	3.2	208
22	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. <i>Clinical Cancer Research</i> , 2019, 25, 6916-6924.	3.2	200
23	Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1001-1011.	1.9	187
24	A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 209-214.	3.2	174
25	Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1051-1061.	0.8	174
26	Immunotherapy of Prostate Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2017, 23, 6764-6770.	3.2	173
27	Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. , 2018, 6, 35.		172
28	Dual targeting of TGF- β 2 and PD-L1 via a bifunctional anti-PD-L1/TGF- β 2RII agent: status of preclinical and clinical advances. , 2020, 8, e000433.		166
29	Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. , 2019, 7, 240.		162
30	A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy. <i>Clinical Cancer Research</i> , 2007, 13, 958-964.	3.2	150
31	Effects of conventional therapeutic interventions on the number and function of regulatory T cells. <i>Oncolmmunology</i> , 2013, 2, e27025.	2.1	148
32	An update on androgen deprivation therapy for prostate cancer. <i>Endocrine-Related Cancer</i> , 2010, 17, R305-R315.	1.6	147
33	Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 4526-4531.	3.2	141
34	Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	139
35	A novel bifunctional anti-PD-L1/TGF- β 2 Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. <i>Oncolmmunology</i> , 2017, 6, e1349589.	2.1	137
36	Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2070-2076.	0.8	136

#	ARTICLE	IF	CITATIONS
37	Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. <i>Cancer Biology and Therapy</i> , 2006, 5, 22-27.	1.5	135
38	If we build it they will come: targeting the immune response to breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 37.	2.3	132
39	Enhanced Functionality of CD4 ⁺ CD25 ^{high} FoxP3 ⁺ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 1032-1040.	3.2	131
40	Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression. <i>Oncologist</i> , 2010, 15, 969-975.	1.9	131
41	Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 4957.	3.0	130
42	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2019, 24, 1259-1269.	1.9	127
43	Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma. <i>JAMA Oncology</i> , 2019, 5, 351.	3.4	127
44	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. , 2020, 8, e000398.		125
45	Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time. <i>Journal of Urology</i> , 2008, 179, 2181-2186.	0.2	122
46	Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. , 2018, 6, 111.		122
47	Clinical Safety of a Viral Vector Based Prostate Cancer Vaccine Strategy. <i>Journal of Urology</i> , 2007, 178, 1515-1520.	0.2	119
48	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β 2 and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1210-1222.	0.5	119
49	Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. <i>Cancer Immunology Research</i> , 2015, 3, 1248-1256.	1.6	118
50	Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase 1b trial: Safety and clinical activity.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5533-5533.	0.8	117
51	First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 99-109.	3.2	116
52	Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents. <i>Cancer Investigation</i> , 2009, 27, 221-226.	0.6	115
53	Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 133-141.	1.6	115
54	Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2009, 103, 1636-1640.	1.3	112

#	ARTICLE	IF	CITATIONS
55	A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7164-7173.	3.2	111
56	Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research. <i>Clinical Cancer Research</i> , 2011, 17, 3884-3891.	3.2	110
57	White paper on microbial anti-cancer therapy and prevention. , 2018, 6, 78.		108
58	Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant. <i>Clinical Cancer Research</i> , 2008, 14, 5284-5291.	3.2	107
59	Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. <i>Blood</i> , 2012, 120, 3030-3038.	0.6	107
60	A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. <i>Seminars in Oncology</i> , 2001, 28, 62-66.	0.8	107
61	ANTIANDROGEN, VACCINE AND COMBINATION THERAPY IN PATIENTS WITH NONMETASTATIC HORMONE REFRACTORY PROSTATE CANCER. <i>Journal of Urology</i> , 2005, 174, 539-546.	0.2	106
62	Discovering Clinical Biomarkers of Ionizing Radiation Exposure with Serum Proteomic Analysis. <i>Cancer Research</i> , 2006, 66, 1844-1850.	0.4	105
63	A retrospective study of the time to clinical endpoints for advanced prostate cancer. <i>BJU International</i> , 2005, 96, 985-989.	1.3	102
64	A phase II study of perfosine in androgen independent prostate cancer. <i>Cancer Biology and Therapy</i> , 2005, 4, 1133-1137.	1.5	98
65	Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 150-152.	0.5	97
66	The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. <i>Oncotarget</i> , 2016, 7, 37762-37772.	0.8	96
67	Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. , 2019, 7, 269.		94
68	Impact of Tumour Volume on the Potential Efficacy of Therapeutic Vaccines. <i>Current Oncology</i> , 2011, 18, 150-157.	0.9	90
69	Anti-“PD-L1 Treatment Induced Central Diabetes Insipidus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 365-369.	1.8	88
70	Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 225-234.	2.0	86
71	A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 407-418.	2.0	82
72	Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. <i>Cancer</i> , 2018, 124, 2010-2017.	2.0	81

#	ARTICLE	IF	CITATIONS
73	Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 1087.	3.4	80
74	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- β 2 and PD-L1, in patients with human papillomavirus-associated malignancies. , 2020, 8, e001395.		79
75	Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5509-5509.	0.8	79
76	Prospective Study Evaluating Na ¹⁸ F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 886-892.	2.8	78
77	Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. , 2017, 5, 20.		78
78	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3672-3684.	0.8	78
79	Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines. <i>Seminars in Oncology</i> , 2012, 39, 296-304.	0.8	75
80	A PROSPECTIVE ANALYSIS OF THE TIME TO NORMALIZATION OF SERUM ANDROGENS FOLLOWING 6 MONTHS OF ANDROGEN DEPRIVATION THERAPY IN PATIENTS ON A RANDOMIZED PHASE III CLINICAL TRIAL USING LIMITED HORMONAL THERAPY. <i>Journal of Urology</i> , 2005, 173, 1567-1571.	0.2	73
81	Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. <i>Oncology</i> , 2008, 22, 1064-70; discussion 1075, 1080-1, 1084.	0.4	72
82	The Kinetics and Reproducibility of ¹⁸ F-Sodium Fluoride for Oncology Using Current PET Camera Technology. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1175-1184.	2.8	71
83	Radium-223 mechanism of action: implications for use in treatment combinations. <i>Nature Reviews Urology</i> , 2019, 16, 745-756.	1.9	71
84	PANVAC α -VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 543-554.	1.4	70
85	Therapeutic Cancer Vaccines. <i>Advances in Cancer Research</i> , 2014, 121, 67-124.	1.9	68
86	Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 12.		67
87	A RANDOMIZED, PHASE II TRIAL OF KETOCONAZOLE PLUS ALENDRONATE VERSUS KETOCONAZOLE ALONE IN PATIENTS WITH ANDROGEN INDEPENDENT PROSTATE CANCER AND BONE METASTASES. <i>Journal of Urology</i> , 2005, 173, 790-796.	0.2	66
88	Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. <i>Clinical Cancer Research</i> , 2002, 8, 41-53.	3.2	66
89	Enhancing efficacy of therapeutic vaccinations by combination with other modalities. <i>Vaccine</i> , 2007, 25, B89-B96.	1.7	63
90	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63

#	ARTICLE	IF	CITATIONS
91	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. <i>Journal of Nuclear Medicine</i> , 2022, 63, 59-68.	2.8	61
92	A Human Cytotoxic T-Lymphocyte Epitope and Its Agonist Epitope from the Nonvariable Number of Tandem Repeat Sequence of MUC-1. <i>Clinical Cancer Research</i> , 2004, 10, 2139-2149.	3.2	60
93	A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. <i>BJU International</i> , 2008, 102, 617-621.	1.3	60
94	Effect of TLR Agonists on the Differentiation and Function of Human Monocytic Myeloid-Derived Suppressor Cells. <i>Journal of Immunology</i> , 2015, 194, 4215-4221.	0.4	60
95	Strategies for improving the management of immune-related adverse events. , 2020, 8, e001754.		60
96	Soluble CD27-Pool in Humans May Contribute to T Cell Activation and Tumor Immunity. <i>Journal of Immunology</i> , 2013, 190, 6250-6258.	0.4	59
97	Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1099-1109.	5.1	59
98	Prostate Cancer Immunotherapy: Figure 1.. <i>Clinical Cancer Research</i> , 2011, 17, 5233-5238.	3.2	57
99	Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 124-125.	0.8	56
100	A phase I study of TRC105 anti- <i>endoglin</i> (CD105) antibody in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2015, 116, 546-555.	1.3	55
101	Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab. <i>Molecular Imaging</i> , 2019, 18, 153601211982998.	0.7	55
102	TRICOM Vector Based Cancer Vaccines. <i>Current Pharmaceutical Design</i> , 2006, 12, 351-361.	0.9	53
103	A Viral Vaccine Encoding Prostate-Specific Antigen Induces Antigen Spreading to a Common Set of Self-Proteins in Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2010, 16, 4046-4056.	3.2	53
104	Dual inhibition of TGF β 2 and PD-L1: a novel approach to cancer treatment. <i>Molecular Oncology</i> , 2022, 16, 2117-2134.	2.1	53
105	Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 650-660.	1.0	52
106	Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 197-206.	2.0	51
107	Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer. , 2018, 6, 91.		51
108	Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. <i>Oncologist</i> , 2020, 25, 290-300.	1.9	51

#	ARTICLE	IF	CITATIONS
109	Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. <i>Clinical Cancer Research</i> , 2017, 23, 6833-6845.	3.2	51
110	Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF. <i>Clinical Cancer Research</i> , 2013, 19, 1290-1299.	3.2	50
111	Nivolumab: Promising Survival Signal Coupled With Limited Toxicity Raises Expectations. <i>Journal of Clinical Oncology</i> , 2014, 32, 986-988.	0.8	50
112	Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. <i>Journal of Circulating Biomarkers</i> , 2016, 5, 5.	0.8	50
113	Product review: avelumab, an anti-PD-L1 antibody. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 891-908.	1.4	50
114	Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. <i>European Urology</i> , 2021, 80, 746-757.	0.9	50
115	Costimulatory Molecules as Adjuvants for Immunotherapy. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 788.	3.0	49
116	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2219-2231.	1.4	49
117	Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. , 2020, 8, e001246.		49
118	PART V. Modulation of Antitumor Vaccine Strategies Preclinical and Clinical Studies of Recombinant Poxvirus Vaccines for Carcinoma Therapy. <i>Critical Reviews in Immunology</i> , 2007, 27, 451-462.	1.0	49
119	Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. , 2019, 7, 275.		48
120	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- β 2 and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. , 2020, 8, e000664.		48
121	The use of bisphosphonates in cancer patients. <i>Acta Oncologica</i> , 2007, 46, 581-591.	0.8	47
122	Augmented Radiologist Workflow Improves Report Value and Saves Time: A Potential Model for Implementation of Artificial Intelligence. <i>Academic Radiology</i> , 2020, 27, 96-105.	1.3	47
123	Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. <i>BJU International</i> , 2007, 99, 1047-1055.	1.3	45
124	A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. <i>Clinical Cancer Research</i> , 2019, 25, 4933-4944.	3.2	45
125	Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. <i>Journal of the National Cancer Institute</i> , 2020, 112, 562-573.	3.0	45
126	Analyses of Recombinant Vaccinia and Fowlpox Vaccine Vectors Expressing Transgenes for Two Human Tumor Antigens and Three Human Costimulatory Molecules. <i>Clinical Cancer Research</i> , 2005, 11, 1597-1607.	3.2	44

#	ARTICLE	IF	CITATIONS
127	Analyses of functions of an anti-PD-L1/TGF β 2R2 bispecific fusion protein (M7824). <i>Oncotarget</i> , 2017, 8, 75217-75231.	0.8	44
128	Paradigm Shifts in Cancer Vaccine Therapy. <i>Experimental Biology and Medicine</i> , 2008, 233, 522-534.	1.1	43
129	A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: ECOG 9802. <i>European Urology</i> , 2015, 68, 365-371.	0.9	43
130	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8503-8503.	0.8	43
131	Therapeutic vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 219-221.	1.4	42
132	A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation. <i>Journal of Urology</i> , 2009, 181, 1104-1113.	0.2	41
133	Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E1749-58.	3.3	41
134	Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer. , 2020, 8, e000655.		41
135	Combining radiation and immunotherapy for synergistic antitumor therapy. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 37-42.	2.8	41
136	A Randomized Phase II Study of Docetaxel Alone or in Combination with PANVAC α , γ -V (Vaccinia) and PANVAC α , γ -F (Fowlpox) in Patients with Metastatic Breast Cancer (NCI 05-C-0229). <i>Clinical Breast Cancer</i> , 2006, 7, 176-179.	1.1	40
137	Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2013, 111, 1269-1280.	1.3	40
138	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 77-85.	0.9	40
139	A Prospective Comparison of ¹⁸ F-Sodium Fluoride PET/CT and PSMA-Targeted ¹⁸ F-DCFB PET/CT in Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1665-1671.	2.8	40
140	A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. <i>Oncologist</i> , 2020, 25, 479-e899.	1.9	39
141	Increased Frequency of Venous Thromboembolism with the Combination of Docetaxel and Thalidomide in Patients with Metastatic Androgen-Independent Prostate Cancer. <i>Pharmacotherapy</i> , 2003, 23, 315-318.	1.2	38
142	Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1521-1531.	2.0	38
143	Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy. <i>Expert Review of Vaccines</i> , 2018, 17, 697-705.	2.0	38
144	Samarium-153-EDTMP (Quadramet $\text{\textcircled{R}}$) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. <i>Oncotarget</i> , 2016, 7, 69014-69023.	0.8	38

#	ARTICLE	IF	CITATIONS
145	ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody. <i>International Journal of Cancer</i> , 2017, 141, 583-593.	2.3	37
146	Therapeutic Vaccines for Prostate Cancer. <i>Oncologist</i> , 2006, 11, 451-462.	1.9	36
147	Kinetics of Serum Androgen Normalization and Factors Associated With Testosterone Reserve After Limited Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer. <i>Journal of Urology</i> , 2008, 180, 1432-1437.	0.2	36
148	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. <i>Cancer Immunology Research</i> , 2016, 4, 755-765.	1.6	36
149	Combining immunotherapies for the treatment of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 694-700.	0.8	36
150	Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF- β 2, in patients with HPV associated cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3007-3007.	0.8	36
151	Targeting the Immune System in Nonâ€“Small-Cell Lung Cancer: Bridging the Gap Between Promising Concept and Therapeutic Reality. <i>Clinical Lung Cancer</i> , 2010, 11, 228-237.	1.1	35
152	Poxviral vectors for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 463-478.	1.4	35
153	Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. , 2019, 7, 119.		35
154	A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.. <i>Journal of Clinical Oncology</i> , 2018, 36, 163-163.	0.8	35
155	Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 109-117.	2.0	34
156	Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. , 2022, 10, e003392.		34
157	Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 19-28.	1.4	32
158	A Phase I Clinical Study of High Dose Ketoconazole Plus Weekly Docetaxel for Metastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2010, 183, 2219-2226.	0.2	32
159	The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. <i>Oncotarget</i> , 2015, 6, 31344-31359.	0.8	32
160	Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. <i>ELife</i> , 2020, 9, .	2.8	32
161	Upâ€“regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castrationâ€“resistant prostate cancer. <i>International Journal of Cancer</i> , 2013, 133, 373-382.	2.3	31
162	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. , 2016, 4, 92.		31

#	ARTICLE	IF	CITATIONS
163	Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. <i>Oncologist</i> , 2021, 26, e847-e858.	1.9	31
164	Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3064-3064.	0.8	31
165	A Phase I Study of Oral CC-5013 (Lenalidomide, Revlimid [®]), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer. <i>Clinical Prostate Cancer</i> , 2004, 2, 241-243.	2.1	29
166	Promising novel immunotherapies and combinations for prostate cancer. <i>Future Oncology</i> , 2009, 5, 187-196.	1.1	29
167	HEPCIDIN, ANAEMIA, AND PROSTATE CANCER. <i>BJU International</i> , 2011, 107, 678-679.	1.3	29
168	New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 63-71.	2.0	28
169	Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. <i>Oncolmmunology</i> , 2016, 5, e1107698.	2.1	28
170	A case report of multiple primary prostate tumors with differential drug sensitivity. <i>Nature Communications</i> , 2020, 11, 837.	5.8	28
171	Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma. , 2021, 9, e002097.		28
172	Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4501-4501.	0.8	28
173	Vaccines as an Integral Component of Cancer Immunotherapy. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2195.	3.8	27
174	Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report. , 2018, 6, 150.		27
175	Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2469-2474.	1.4	26
176	Cognitive testing of tobacco use items for administration to patients with cancer and cancer survivors in clinical research. <i>Cancer</i> , 2016, 122, 1728-1734.	2.0	26
177	Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 367-367.	0.8	26
178	Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), Decreases Human T Regulatory Lymphocytes while Preserving Effector T Lymphocytes: A Rationale for Its Use in Combination Immunotherapy. <i>Journal of Immunology</i> , 2014, 192, 2622-2633.	0.4	25
179	Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). , 2021, 9, e002374.		25
180	Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3044-3044.	0.8	25

#	ARTICLE	IF	CITATIONS
181	PSA-based vaccines for the treatment of prostate cancer. <i>Expert Review of Vaccines</i> , 2006, 5, 199-209.	2.0	24
182	A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1409-1418.	1.4	24
183	The role of soluble CD40L in immunosuppression. <i>Oncolmmunology</i> , 2013, 2, e22546.	2.1	24
184	TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. <i>Oncolmmunology</i> , 2016, 5, e1197459.	2.1	24
185	Pulmonary Toxicity During Prostate Cancer Treatment With Docetaxel and Thalidomide. <i>American Journal of Therapeutics</i> , 2003, 10, 228-232.	0.5	23
186	Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. <i>Expert Review of Vaccines</i> , 2011, 10, 141-150.	2.0	23
187	Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 229-237.	0.9	23
188	Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 161-174.	2.0	23
189	Phase III trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2016, 118, 590-597.	1.3	23
190	Maturation of human dendritic cells with <i>Saccharomyces cerevisiae</i> (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells. <i>Vaccine</i> , 2011, 29, 4992-4999.	1.7	22
191	Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. <i>Clinical Cancer Research</i> , 2021, 27, 429-437.	3.2	22
192	Immunotherapy biomarkers 2016: overcoming the barriers. , 2017, 5, 29.		21
193	Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- β 2, in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3006-3006.	0.8	21
194	M7824: A promising new strategy to combat cancer immune evasion. <i>Oncoscience</i> , 2018, 5, 269-270.	0.9	21
195	Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2014, 3, 403-5.	1.3	21
196	Chemotherapy for Prostate Cancer. <i>American Journal of Therapeutics</i> , 2004, 11, 288-294.	0.5	20
197	From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. <i>Expert Review of Vaccines</i> , 2011, 10, 743-753.	2.0	20
198	Demystifying Immunotherapy in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 50-58.	1.0	20

#	ARTICLE	IF	CITATIONS
199	Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 895-901.	1.4	20
200	Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1391-1398.	3.2	20
201	Treatment options for androgen-independent prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2003, 1, 49-57.	0.3	20
202	Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4). <i>International Journal of Cancer</i> , 2007, 121, 595-605.	2.3	19
203	Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity. <i>OncImmunology</i> , 2012, 1, 1167-1168.	2.1	19
204	Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. <i>Therapeutic Advances in Vaccines</i> , 2014, 2, 137-148.	2.7	19
205	Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. , 2021, 9, e003238.		19
206	Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3055-3055.	0.8	19
207	Tumor in the Crossfire: Inhibiting TGF- β 2 to Enhance Cancer Immunotherapy. <i>BioDrugs</i> , 2022, 36, 153-180.	2.2	19
208	Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4514-4514.	0.8	18
209	ABO blood type correlates with survival on prostate cancer vaccine therapy. <i>Oncotarget</i> , 2015, 6, 32244-32256.	0.8	18
210	A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer. <i>Oncologist</i> , 2022, 27, 198-209.	1.9	18
211	Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF- β 2 blockade in HPV-unrelated head and neck cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	18
212	Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis. <i>JAMA Network Open</i> , 2020, 3, e200032.	2.8	17
213	Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors. <i>Oncologist</i> , 2020, 25, 560.	1.9	17
214	Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure. <i>Annals of Oncology</i> , 2020, 31, 369-376.	0.6	17
215	Future directions in tumor immunotherapy: CTLA4 blockade. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 136-137.	4.3	16
216	Persistent Hypocalcemia Induced by Zoledronic Acid in a Patient with Androgen-Independent Prostate Cancer and Extensive Bone Metastases. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 403-405.	0.9	16

#	ARTICLE	IF	CITATIONS
217	A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. <i>European Urology Focus</i> , 2018, 4, 636-638.	1.6	16
218	Efficacy and immune-related adverse event associations in avelumab-treated patients. , 2020, 8, e001427.		16
219	Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. , 2020, 8, e001064.		16
220	Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival. , 2022, 10, e003302.		16
221	Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 351.	1.3	15
222	Editorial: Local Immunotherapy: A Way to Convert Tumors From "Cold" to "Hot". <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	15
223	Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. <i>Asian Journal of Andrology</i> , 2014, 16, 364.	0.8	15
224	IgG Responses to Tissue-Associated Antigens as Biomarkers of Immunological Treatment Efficacy. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-10.	3.0	14
225	Poxviral-based vaccine elicits immunologic responses in prostate cancer patients. <i>Oncolimmunology</i> , 2014, 3, e28611.	2.1	14
226	Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST. <i>BMC Cancer</i> , 2016, 16, 672.	1.1	14
227	A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer. <i>Frontiers in Endocrinology</i> , 2020, 11, 490.	1.5	14
228	Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2501-2501.	0.8	14
229	Deep Small Bowel Segmentation with Cylindrical Topological Constraints. <i>Lecture Notes in Computer Science</i> , 2020, 12264, 207-215.	1.0	14
230	A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel.. <i>Journal of Clinical Oncology</i> , 2013, 31, 102-102.	0.8	14
231	Novel Clinical Trials in Androgen-Independent Prostate Cancer. <i>Clinical Prostate Cancer</i> , 2002, 1, 51-57.	2.1	13
232	Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer. <i>Future Oncology</i> , 2005, 1, 19-22.	1.1	13
233	Re: Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1106-1106.	3.0	13
234	Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management. , 2020, 8, e001019.		13

#	ARTICLE	IF	CITATIONS
235	Abstract CT075: Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF- β 2 and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies. , 2019, , .		13
236	Therapeutic Vaccines and Immunotherapy in Castration-Resistant Prostate Cancer: Current Progress and Clinical Applications. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e166-e170.	1.8	13
237	Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 5026-5026.	0.8	13
238	M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- β 2, in patients with heavily pretreated CRC: Preliminary results from a phase I trial.. Journal of Clinical Oncology, 2018, 36, 764-764.	0.8	13
239	A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion. Oncotarget, 2018, 9, 37676-37688.	0.8	13
240	Perspectives on the clinical development of immunotherapy in prostate cancer. Asian Journal of Andrology, 2018, 20, 253.	0.8	13
241	Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient. Urology, 2003, 62, 147-154.	0.5	12
242	Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer. Expert Review of Vaccines, 2003, 2, 483-493.	2.0	12
243	Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. Immunotherapy, 2011, 3, 27-31.	1.0	12
244	Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy. Prostate Cancer and Prostatic Diseases, 2012, 15, 289-295.	2.0	12
245	Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report. BMC Cancer, 2019, 19, 539.	1.1	12
246	Deep Learning Based Staging of Bone Lesions From Computed Tomography Scans. IEEE Access, 2021, 9, 87531-87542.	2.6	12
247	Dual PD-L1 and TGF- β blockade in patients with recurrent respiratory papillomatosis. , 2021, 9, e003113.		12
248	A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). Prostate Cancer and Prostatic Diseases, 2022, 25, 735-740.	2.0	12
249	Strategies for Optimizing the Clinical Impact of Immunotherapeutic Agents Such as Sipuleucel-T in Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1505-1512.	2.3	11
250	Developing immunotherapy strategies in the treatment of prostate cancer. Asian Journal of Urology, 2016, 3, 278-285.	0.5	11
251	Resources Required for Semi-Automatic Volumetric Measurements in Metastatic Chordoma: Is Potentially Improved Tumor Burden Assessment Worth the Time Burden?. Journal of Digital Imaging, 2016, 29, 357-364.	1.6	11
252	Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. Clinical Genitourinary Cancer, 2020, 18, 258-267.e1.	0.9	11

#	ARTICLE	IF	CITATIONS
253	Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 581801.	1.3	11
254	Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2526-2526.	0.8	11
255	Exposure-response and PD-L1 expression analysis of second-line avelumab in patients with advanced NSCLC: Data from the JAVELIN Solid Tumor trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9086-9086.	0.8	11
256	Novel Therapeutic Strategies in Prostate Cancer. <i>Cancer Biology and Therapy</i> , 2004, 3, 371-376.	1.5	10
257	Phase I Trial of an Enhanced Prostate-Specific Antigenâ€‘Based Vaccine and Antiâ€‘CTLA-4 Antibody in Patients with Metastatic Androgen-Independent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 347-350.	0.9	10
258	The Current and Emerging Role of Immunotherapy in Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2010, 8, 10-16.	0.9	10
259	The evolving role of immunotherapy in prostate cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 232-240.	1.1	10
260	Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment. <i>Journal of the National Cancer Institute</i> , 2019, 111, 219-220.	3.0	10
261	Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. <i>Journal of Nuclear Medicine</i> , 2020, 61, 552-562.	2.8	10
262	Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?. <i>Journal of the National Cancer Institute</i> , 2021, 113, 799-800.	3.0	10
263	Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-Î² and PD-L1, in cervical cancer: Data from phase 1 and phase 2 studies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5509-5509.	0.8	10
264	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: Safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3055-3055.	0.8	10
265	Vaccines as Monotherapy and in Combination Therapy for Prostate Cancer. <i>Clinical and Translational Science</i> , 2010, 3, 116-122.	1.5	9
266	Effect of Talactoferrin Alfa on the Immune System in Adults With Nonâ€‘Small Cell Lung Cancer. <i>Oncologist</i> , 2013, 18, 821-822.	1.9	9
267	Better VISTAs ahead? Potential and pitfalls of immunotherapy. <i>Nature Reviews Urology</i> , 2017, 14, 455-456.	1.9	9
268	Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. , 2021, 9, e001556.		9
269	Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 172-172.	0.8	9
270	Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-Î² and PD-L1.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2566-2566.	0.8	9

#	ARTICLE	IF	CITATIONS
271	Checkpoint and PARP inhibitors, for whom and when. <i>Oncotarget</i> , 2017, 8, 95036-95037.	0.8	9
272	National Cancer Institute Intramural Approach to Advanced Prostate Cancer. <i>Clinical Prostate Cancer</i> , 2002, 1, 153-162.	2.1	8
273	Treatment of Castration-Resistant Prostate Cancer: Updates on Therapeutics Targeting the Androgen Receptor Signaling Pathway. <i>American Journal of Therapeutics</i> , 2010, 17, 176-181.	0.5	8
274	Prostate cancer immunotherapy: the path forward. <i>Current Opinion in Supportive and Palliative Care</i> , 2017, 11, 225-230.	0.5	8
275	A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4534-4534.	0.8	8
276	A randomized, double-blind, phase II clinical trial of GI-6301 (yeast-brachyury vaccine) versus placebo in combination with standard of care definitive radiotherapy in locally advanced, unresectable, chordoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11527-11527.	0.8	8
277	MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays. <i>Cell Reports Methods</i> , 2022, 2, 100136.	1.4	8
278	Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa. , 2022, 10, e004601.		8
279	Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. <i>BJU International</i> , 2007, 99, 525-528.	1.3	7
280	Ipilimumab in prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 303-313.	1.4	7
281	Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vasospasm during first 5-FU infusion. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 1010-1014.	0.6	7
282	The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, 457-467.	0.8	7
283	Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2021, 127, 435-444.	1.3	7
284	Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivolpi) for metastatic genitourinary tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3-3.	0.8	7
285	Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic. , 2021, 9, e002087.		7
286	Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy. , 2021, 9, e002605.		7
287	A comparison of ¹⁸ F-DCFPyL, ¹⁸ F-NaF and ¹⁸ F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262371.	2.8	7
288	Safety and clinical activity of anti-programmed death-ligand 1 (PD-L1) antibody (ab) avelumab (MSB0010718C) in advanced thymic epithelial tumors (TETs).. <i>Journal of Clinical Oncology</i> , 2016, 34, e20106-e20106.	0.8	7

#	ARTICLE	IF	CITATIONS
289	Avelumab (anti-PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial.. Journal of Clinical Oncology, 2018, 36, 9090-9090.	0.8	7
290	Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- β 2 and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9558-9558.	0.8	7
291	Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGF β 2RII agent: Current status. Experimental Biology and Medicine, 2022, 247, 1124-1134.	1.1	7
292	Immunotherapy for Prostate Cancer: What's the Future?. Hematology/Oncology Clinics of North America, 2006, 20, 965-983.	0.9	6
293	Immunotherapy in genitourinary malignancies. Current Opinion in Urology, 2016, 26, 501-507.	0.9	6
294	Avelumab: is it time to get excited?. Expert Review of Anticancer Therapy, 2018, 18, 815-821.	1.1	6
295	9570 Long-term follow-up of patients (pts) with human papillomavirus (HPV)-associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF- β 2 and PD-L1. Annals of Oncology, 2021, 32, S829.	0.6	6
296	Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).. Journal of Clinical Oncology, 2013, 31, 314-314.	0.8	6
297	NCI experience using yeast-brachyury vaccine (GI-6301) in patients (pts) with advanced chordoma.. Journal of Clinical Oncology, 2014, 32, 3081-3081.	0.8	6
298	A randomized, prospective, phase II study to determine the efficacy of BCG given in combination with panvac versus BCG alone in adults with high grade non-muscle invasive bladder cancer who failed at least one induction course of BCG.. Journal of Clinical Oncology, 2014, 32, TPS4590-TPS4590.	0.8	6
299	A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2014, 32, 307-307.	0.8	6
300	PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide.. Journal of Clinical Oncology, 2020, 38, 105-105.	0.8	6
301	Avelumab for the treatment of metastatic Merkel cell carcinoma. Drugs of Today, 2017, 53, 377.	0.7	6
302	A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1. Journal of Immunological Methods, 2003, 279, 183-192.	0.6	5
303	Clodronate in the prevention and treatment of skeletal metastasis. Expert Review of Anticancer Therapy, 2005, 5, 221-230.	1.1	5
304	A Phase I Feasibility Study of an Intraprostatic Prostate-Specific Antigen-Based Vaccine in Patients with Prostate Cancer with Local Failure After Radiation Therapy or Clinical Progression on Androgen-Deprivation Therapy in the Absence of Local Definitive Therapy. Clinical Genitourinary Cancer, 2006, 5, 89-92.	0.9	5
305	Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. International Journal of Cancer, 2014, 135, 862-870.	2.3	5
306	Prospects for the future of prostate cancer vaccines. Expert Review of Vaccines, 2016, 15, 271-274.	2.0	5

#	ARTICLE	IF	CITATIONS
307	Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016. , 2017, 5, 55.		5
308	A Case of Anti-“PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema. Clinical Genitourinary Cancer, 2019, 17, e549-e552.	0.9	5
309	Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, 207-207.	0.8	5
310	Effect of PSA-tricom, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa.. Journal of Clinical Oncology, 2013, 31, 57-57.	0.8	5
311	Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2015, 33, TPS5081-TPS5081.	0.8	5
312	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced adrenocortical carcinoma from the JAVELIN solid tumor phase Ib trial: Safety and clinical activity.. Journal of Clinical Oncology, 2016, 34, 4516-4516.	0.8	5
313	Safety profile of avelumab in patients with advanced solid tumors: A JAVELIN pooled analysis of phase 1 and 2 data.. Journal of Clinical Oncology, 2017, 35, 3059-3059.	0.8	5
314	Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial.. Journal of Clinical Oncology, 2018, 36, 166-166.	0.8	5
315	Immunotherapy for biochemically recurrent prostate cancer.. Journal of Clinical Oncology, 2018, 36, 215-215.	0.8	5
316	Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer.. Journal of Clinical Oncology, 2018, 36, 248-248.	0.8	5
317	Acquired Coagulopathy With Immune Checkpoint Inhibitors: An Underrecognized Association Between Inflammation and Coagulation. JTO Clinical and Research Reports, 2020, 1, 100049.	0.6	5
318	Cancer vaccines: current directions and perspectives in prostate cancer. Current Opinion in Molecular Therapeutics, 2009, 11, 31-6.	2.8	5
319	Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity. JCI Insight, 2022, 7, .	2.3	5
320	The Emerging Role of Bisphosphonates in Prostate Cancer. American Journal of Therapeutics, 2004, 11, 60-73.	0.5	4
321	Prolonged Response to Nilutamide in a Patient with Stage D0.5 Prostate Cancer Who Previously Failed Androgen Deprivation Therapy. American Journal of Therapeutics, 2005, 12, 172-174.	0.5	4
322	Immunologic Monitoring of Cellular Immune Responses in Cancer Vaccine Therapy. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-3.	3.0	4
323	Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer. Cancers, 2012, 4, 1333-1348.	1.7	4
324	Progress in prostate cancer imaging. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 938-939.	0.8	4

#	ARTICLE	IF	CITATIONS
325	Adding fuel to the fire: Immunogenic intensification. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3306-3312.	1.4	4
326	(R)Evolutionary Therapy: The Potential of Immunotherapy to Fulfill the Promise of Personalized Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju347-dju347.	3.0	4
327	Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1769-1781.	1.4	4
328	MP15-10 IMMUNOLOGIC RESPONSE TO A THERAPEUTIC CANCER VACCINE (PANVAC): INITIAL RESULTS FROM A RANDOMIZED PHASE 2 CLINICAL TRIAL. <i>Journal of Urology</i> , 2017, 197, .	0.2	4
329	mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 352.e25-352.e30.	0.8	4
330	Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma. <i>Cancer Gene Therapy</i> , 2020, 27, 438-447.	2.2	4
331	A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS192-TPS192.	0.8	4
332	Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- β 2 and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2021, 39, 6020-6020.	0.8	4
333	MP16-14 CLINICAL OUTCOMES OF A RANDOMIZED, PROSPECTIVE, PHASE II STUDY TO DETERMINE THE EFFICACY OF BACILLUS CALMETTE-GUERIN (BCG) GIVEN IN COMBINATION WITH PANVAC VERSUS BCG GIVEN ALONE IN ADULTS WITH HIGH GRADE BCG-REFRACTORY NON-MUSCLE INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2021, 206, .	0.2	4
334	Abstract 4901: Short-course enzalutamide reveals immune activating properties in patients with biochemically recurrent prostate cancer. <i>Cancer Research</i> , 2016, 76, 4901-4901.	0.4	4
335	Clinical and immunologic impact of short course enzalutamide without androgen deprivation therapy for biochemically recurrent prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 214-214.	0.8	4
336	Infusion-related reactions with administration of avelumab: mild and manageable side effects. <i>Translational Cancer Research</i> , 2017, 6, S1296-S1298.	0.4	4
337	Therapeutic Vaccines and Immunotherapy in Castration-Resistant Prostate Cancer: Current Progress and Clinical Applications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e166-e170.	1.8	4
338	A Pilot Trial of a Carcinoembryonic Antigen/TRICOM-Based Vaccine and Radiation to Liver Metastases in Patients with Carcinoembryonic Antigen-Positive Solid Tumors. <i>Clinical Colorectal Cancer</i> , 2006, 6, 72-75.	1.0	3
339	Significant Prostate-Specific Antigen (PSA) Response to Low-Dose Ketoconazole in a Patient With Non-Metastatic Androgen-Independent Prostate Cancer (AIPC) and a Review of the Literature. <i>American Journal of Therapeutics</i> , 2007, 14, 310-313.	0.5	3
340	Initial PSA Oscillations Precede Prolonged Stable Disease in a Patient Treated With a Therapeutic Cancer Vaccine. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 43-46.	0.9	3
341	Dramatic and Prolonged PSA Response After Retreatment With a PSA Vaccine. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 362-364.	0.9	3
342	Moving the goal posts in prostate cancer trials. <i>Lancet Oncology</i> , The, 2015, 16, 247-249.	5.1	3

#	ARTICLE	IF	CITATIONS
343	Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I/II). <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4599-TPS4599.	1.1	3
344	A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4599-TPS4599.	0.8	3
345	A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5096-TPS5096.	0.8	3
346	Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4569-4569.	0.8	3
347	Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 191-191.	0.8	3
348	Avelumab demonstrates promise in advanced NSCLC. <i>Oncotarget</i> , 2017, 8, 102767-102768.	0.8	3
349	A phase I study of TRC105 (Anti-CD105 [endoglin] antibody) in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 3043-3043.	0.8	3
350	Therapeutic prostate cancer vaccines: a review of the latest developments. <i>Current Opinion in Investigational Drugs</i> , 2008, 9, 1296-301.	2.3	3
351	Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 93-93.	0.8	3
352	CAR T cells reach clinical milestone in prostate cancer. <i>Nature Medicine</i> , 2022, , .	15.2	3
353	A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide. <i>Oncologist</i> , 2022, 27, 718-e694.	1.9	3
354	Vaccine Therapy for a Patient with Androgen-Insensitive Prostate Cancer without Evidence of Measurable Disease on Scans. <i>American Journal of Therapeutics</i> , 2004, 11, 238-241.	0.5	2
355	Early Treatment Gets the Benefit. <i>Journal of Clinical Oncology</i> , 2006, 24, 5172-5173.	0.8	2
356	Toward an off-the-shelf vaccine for B-cell malignancies. <i>Blood</i> , 2012, 120, 1539-1540.	0.6	2
357	The impact of leukapheresis on immune-cell number and function in patients with advanced cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1429-1435.	2.0	2
358	Fast Clearance of the SARS-CoV-2 Virus in a Patient Undergoing Vaccine Immunotherapy for Metastatic Chordoma: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 603248.	1.3	2
359	681P Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic) T1-T2 prostate cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS6092-TPS6092.	0.6	2
360	First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS6092-TPS6092.	0.8	2

#	ARTICLE	IF	CITATIONS
361	A phase I trial of a recombinant CEA yeast-based vaccine targeting CEA-expressing cancers.. Journal of Clinical Oncology, 2012, 30, 458-458.	0.8	2
362	A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, 117-117.	0.8	2
363	A phase I study of a yeast-based therapeutic cancer vaccine, GI-6301, targeting brachyury in patients with metastatic carcinoma.. Journal of Clinical Oncology, 2014, 32, e14026-e14026.	0.8	2
364	A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 108-108.	0.8	2
365	Antibody dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody, avelumab (MSB0010718C), on human tumor cells.. Journal of Clinical Oncology, 2015, 33, 3038-3038.	0.8	2
366	Avelumab in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 5037-5037.	0.8	2
367	Effect of rilimogene galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatectomy.. Journal of Clinical Oncology, 2018, 36, 5083-5083.	0.8	2
368	Current Perspectives in Prostate Cancer Vaccines. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 1052-1057.	0.9	2
369	Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer.. Journal of Clinical Oncology, 2015, 33, e14008-e14008.	0.8	2
370	Abstract OT1-08-01: A phase Ib trial of sequential combinations of BN-brachyury, entinostat, ado-trastuzumab emtansine (T-DM1) and bintrafusp alfa (M7824) in advanced stage breast cancer (BrEAsT). Cancer Research, 2020, 80, OT1-08-01-OT1-08-01.	0.4	2
371	A rare insight into the immunosuppressive landscape of prostate cancer bone metastases. Cancer Cell, 2021, 39, 1450-1452.	7.7	2
372	Resistance to Immunotherapy: Mechanisms and Means for Overcoming. Advances in Experimental Medicine and Biology, 2021, 1342, 45-80.	0.8	2
373	OUP accepted manuscript. Oncologist, 2022, 27, e353-e356.	1.9	2
374	Treating systemic prostate cancer: emerging drug targets and therapies. Expert Opinion on Therapeutic Targets, 2000, 4, 751-763.	1.0	1
375	Therapeutic vaccines for prostate cancer: what have we learned?. Therapy: Open Access in Clinical Medicine, 2008, 5, 3-5.	0.2	1
376	Recombinant TRICOM-based Therapeutic Cancer Vaccines. , 2013, , 309-331.		1
377	970 PROSPECT: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 EFFICACY TRIAL OF PROSTVAC-VF IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. Journal of Urology, 2013, 189, .	0.2	1
378	Impact of androgen deprivation therapy on the thymus and the production of naïve T-cells. , 2013, 1, .		1

#	ARTICLE	IF	CITATIONS
379	Intermediate efficacy end points to assess modern therapies. <i>Nature Reviews Urology</i> , 2013, 10, 686-687.	1.9	1
380	Radium-223 in prostate cancer: emitting the right signals. <i>Lancet Oncology</i> , The, 2016, 17, 1186-1187.	5.1	1
381	14937 Keratoacanthomas associated with anti-TGF- β 2 immunotherapy. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB24.	0.6	1
382	643P Evaluating biomarkers in metastatic castration resistant prostate cancer (mCRPC) patients (Pts) treated with enzalutamide (Enza): PSA, circulating tumor cell (CTC) counts, AR-V7 status, PET imaging vs. CT & Tc99 scans. <i>Annals of Oncology</i> , 2020, 31, S527-S528.	0.6	1
383	Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 601452.	1.3	1
384	Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis. , 2021, 9, e002252.		1
385	Anaplastic features (AnaF) and DNA-damage repair pathway (DDR) mutations in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 92-92.	0.8	1
386	Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, e17044-e17044.	0.8	1
387	CD4+ T-cell count eligibility by HIV status among participants receiving immunotherapy for cancer diagnoses.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12104-12104.	0.8	1
388	TRICOM Poxviral-Based Vaccines for the Treatment of Cancer. , 2014, , 291-327.		1
389	456â€¦Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy. , 2020, , .		1
390	Abstract 5520: Therapeutic vaccination with epitope-enhanced and wild-type TARP peptides in stage DO prostate cancer. , 2011, , .		1
391	Abstract 1586: Recovery and characterization of circulating tumor cells (CTCs) in cryopreserved metastatic castrate-resistant prostate cancer (mCRPC) patient samples. , 2015, , .		1
392	Prospect: A randomized, double-blind, phase III efficacy trial of PROSTVAC.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS4699-TPS4699.	0.8	1
393	Randomized phase II clinical trial to assess MUC1 specific immune response to L-BLP25 vaccine in addition to standard therapy in newly diagnosed high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS4701-TPS4701.	0.8	1
394	Calculation of an immunoscore based on extensive flow cytometry analysis of PBMCs from metastatic breast cancer patients treated with docetaxel alone or in combination with vaccine.. <i>Journal of Clinical Oncology</i> , 2013, 31, 31-31.	0.8	1
395	Impact of standard chemotherapy on peripheral blood immune cell subsets in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 597-597.	0.8	1
396	Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 235-235.	0.8	1

#	ARTICLE	IF	CITATIONS
397	Short course enzalutamide monotherapy in biochemically recurrent prostate cancer: Clinical and immunologic impact.. Journal of Clinical Oncology, 2016, 34, e16619-e16619.	0.8	1
398	Association of efficacy and adverse events of special interest of avelumab in the JAVELIN solid tumor and JAVELIN Merkel 200 trials.. Journal of Clinical Oncology, 2018, 36, 3057-3057.	0.8	1
399	A sequential cohort study of combination immunotherapy with BN-brachyury vaccine, M7824, ALT-803 and epacadostat in metastatic castration-resistant prostate cancer (mCRPC) (QuEST1).. Journal of Clinical Oncology, 2018, 36, TPS3130-TPS3130.	0.8	1
400	A pilot study on the clinical value of 18F-sodium fluoride PET/CT in advanced prostate cancer.. Journal of Clinical Oncology, 2012, 30, 10589-10589.	0.8	1
401	Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations.. Journal of Clinical Oncology, 2013, 31, 128-128.	0.8	1
402	Preliminary results of a prospective study of 18F-NAF PET/CT in prostate cancer.. Journal of Clinical Oncology, 2013, 31, 103-103.	0.8	1
403	Ferumoxylol enhanced MRI for lymph node staging in prostate cancer.. Journal of Clinical Oncology, 2015, 33, 208-208.	0.8	1
404	Abstract 1316: Evaluation of immune cell subsets of cancer patients treated with a fully human IgG1 anti-PD-L1 MAb (MSB0010718C) capable of mediating ADCC of human tumor cells. Cancer Research, 2015, 75, 1316-1316.	0.4	1
405	Personalized peptide vaccine in prostate cancer: capitalizing on existing immunity. Translational Cancer Research, 2016, 5, S1333-S1335.	0.4	1
406	Artificial intelligence assisted bone lesion detection and classification in computed tomography scans of prostate cancer patients.. Journal of Clinical Oncology, 2020, 38, e17567-e17567.	0.8	1
407	Long-term avelumab in advanced non-small-cell lung cancer: summaries and <i>post hoc</i> analyses from JAVELIN Solid Tumor. Future Oncology, 2022, 18, 1333-1342.	1.1	1
408	Therapeutic Vaccines for Colorectal Cancer. American Journal of Cancer, 2004, 3, 299-316.	0.4	0
409	Even More Cost Savings?. Journal of Oncology Practice, 2006, 2, 202-202.	2.5	0
410	176 Vector-based Vaccines for Cancer Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, .	0.9	0
411	Reply to L. LeÅ³n et al. Journal of Clinical Oncology, 2010, 28, e417-e417.	0.8	0
412	Combining radiation and therapeutic cancer vaccines: a synergistic approach. Breast Cancer Management, 2012, 1, 325-335.	0.2	0
413	Combining Vaccines with Therapies that Render Tumor Cells more Susceptible to Immune Mediated Killing. , 2013, , 621-642.		0
414	Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials. Clinical Investigation, 2013, 3, 651-663.	0.0	0

#	ARTICLE	IF	CITATIONS
415	The Use of T Cell Costimulation to Enhance the Immunogenicity of Tumors. , 2014, , 315-334.		0
416	Therapeutic Cancer Vaccines: An Emerging Approach to Cancer Treatment. Cancer Drug Discovery and Development, 2014, , 553-568.	0.2	0
417	PSA. , 2017, , 451-458.		0
418	Pembrolizumab: patient selection or immune intensification?. Nature Reviews Urology, 2018, 15, 593-594.	1.9	0
419	In Reply. Oncologist, 2021, 26, e192-e193.	1.9	0
420	MPA <sub>P</sub>PASS</sub> Enables Stitched Multiplex Multi-Dimensional EV Repertoire Analysis. SSRN Electronic Journal, 0, , .	0.4	0
421	Abstract IA07: The QuEST for an effective immunotherapy for prostate cancer. , 2021, , .		0
422	A phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer.. Journal of Clinical Oncology, 2021, 39, 2617-2617.	0.8	0
423	Anaplastic Features in Advanced Prostate Cancer With and Without DNA Damage Repair Mutations. Clinical Genitourinary Cancer, 2021, 19, e352-e359.	0.9	0
424	605P Analysis of serial PET imaging and paired Tc99 scans in metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide. Annals of Oncology, 2021, 32, S647.	0.6	0
425	HLA-A*03 is a Predictive Biomarker of Poor Response to Immune Checkpoint Blockade in Cancer. SSRN Electronic Journal, 0, , .	0.4	0
426	Cancer Immunology, Immunotherapeutics, and Vaccine Approaches. , 2010, , 305-319.		0
427	Abstract 5524: Generation of cellular immune responses to MUC1-C to target the portion of MUC1 that is most biologically relevant to the transformation process. , 2011, , .		0
428	Abstract SY24-02: Development of recombinant vaccines for the prevention and therapy of human carcinomas. , 2011, , .		0
429	Abstract 758: Cancer vaccine immunotherapy employing Saccharomyces cerevisiae (yeast) as a vector can modulate the balance between CD4+ T cells and regulatory T cells (Tregs) and enhance the specific antitumor immune response. , 2011, , .		0
430	Highlights on FOXO3 and tumor-associated dendritic cells in prostate cancer. Asian Journal of Andrology, 2011, 13, 657-658.	0.8	0
431	Abstract PL03-02: Current status of recombinant pox-viral vaccines. , 2012, , .		0
432	Abstract 5404: Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
433	Abstract 5378: Phase I trial of EUS-guided intratumoral vaccination with recombinant Panvac-F and systemic Panvac-V in patients with locally advanced pancreatic cancer. , 2012, , .		0
434	Abstract 5379: Combination treatment with Bevacizumab, Lenalidomide, Docetaxel and Prednisone (ART-P) does not impact the immune response in patients with metastatic castration-resistant prostate cancer. , 2012, , .		0
435	A pilot trial of a combination of therapeutic vaccines (GI-4000 and GI-6207) as adjunctive therapy with first-line therapy with bevacizumab plus either FOLFOX or FOLFIRI in stage IV patients with newly diagnosed Ras-mutant positive or negative metastatic colorectal cancer.. Journal of Clinical Oncology, 2012, 30, TPS3638-TPS3638.	0.8	0
436	Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies. , 2013, , 455-474.		0
437	PSA. , 2013, , 1-8.		0
438	Abstract IA13: Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. , 2013, , .		0
439	Safety profile of poxviral vaccines: NCI experience.. Journal of Clinical Oncology, 2013, 31, 85-85.	0.8	0
440	Feasibility of continuing docetaxel-based therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) that experience hypersensitivity reactions (HSR).. Journal of Clinical Oncology, 2013, 31, 132-132.	0.8	0
441	Abstract 4571: Autologous TARP peptide vaccination is associated with slowing in PSA velocity and a decrease in tumor growth rate in patients with Stage D0 prostate cancer.. , 2013, , .		0
442	Safety profile of recombinant poxviral TRICOM vaccines.. Journal of Clinical Oncology, 2013, 31, e16036-e16036.	0.8	0
443	Immune impact induced by PSA-tricom, a therapeutic vaccine for prostate cancer.. Journal of Clinical Oncology, 2014, 32, 245-245.	0.8	0
444	A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2014, 32, 218-218.	0.8	0
445	ARv567es as detected in circulating tumor cells: An innovative methodology for the detection of a prognostic and therapeutic biomarker.. Journal of Clinical Oncology, 2014, 32, 112-112.	0.8	0
446	A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 5074-5074.	0.8	0
447	A phase I study of gemcitabine, carboplatin, and lenalidomide for treatment of patients with advanced/metastatic urothelial carcinoma (UC) and other solid tumors.. Journal of Clinical Oncology, 2014, 32, e15527-e15527.	0.8	0
448	A safety study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 5072-5072.	0.8	0
449	Abstract 2544: Identification of immune signatures predicting for clinical outcome measured by flow-cytometry and immunogenetic analysis of PBMCs from breast cancer patients treated with docetaxel alone or docetaxel plus vaccine. , 2014, , .		0
450	Abstract 2546: Analysis of immune cell subsets in a multidrug therapeutic regimen for patients with metastatic castration-resistant prostate cancer. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
451	Abstract 628: Pan-Bcl-2 inhibitor, GX15-070 (Obatoclax), decreases human T regulatory lymphocytes while preserving effector T Lymphocytes: A rationale for its use in combination immunotherapy. , 2014, , .		0
452	Abstract 5012: A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: Immune correlates. , 2014, , .		0
453	Abstract 4815: A novel AR splice variant identified in circulating tumor cells from castration-resistant prostate cancer patient blood as a potentially prognostic biomarker. , 2014, , .		0
454	Association of NaF PET/CT findings with PSA and alkaline phosphatase in untreated castration-sensitive prostate cancer.. Journal of Clinical Oncology, 2015, 33, 122-122.	0.8	0
455	Phase I expansion cohort trial to investigate the safety and clinical activity of avelumab (MSB0010718C) in patients with metastatic or locally advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, TPS3101-TPS3101.	0.8	0
456	Evaluation of a new circulating tumor cell (CTC) platform to predict response and survival in metastatic urothelial carcinoma (UC) patients receiving cabozantinib (cabo).. Journal of Clinical Oncology, 2015, 33, e15501-e15501.	0.8	0
457	The impact of age on sipuleucel-T-induced immune responses.. Journal of Clinical Oncology, 2015, 33, e16009-e16009.	0.8	0
458	Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2015, 33, e16032-e16032.	0.8	0
459	Abstract B100: Panvac-F and Panvac-V: Phase I study of intratumoral and systemic vaccination. , 2015, , .		0
460	Abstract 366: A novel transcript variant of androgen receptor identified in circulating tumor cells from castration-resistant prostate cancer patients as a potentially prognostic biomarker. , 2015, , .		0
461	Abstract CT222: Ferumoxytol enhanced MRI for lymph node staging in genitourinary cancers. , 2015, , .		0
462	Comparison of survival of African-American (AA) patients (pts) in docetaxel (D)-based combination therapies in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 272-272.	0.8	0
463	An analysis of sodium 18f-fluoride PET/CT and prostate specific antigen (PSA) changes in men with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 203-203.	0.8	0
464	An analysis of sodium 18F-fluoride PET/CT and prostate specific antigen (PSA) changes in men with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, e23149-e23149.	0.8	0
465	Abstract CT132: Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody: updated analysis from the phase Ib JAVELIN Solid Tumor trial. , 2016, , .		0
466	Abstract 2048: Pharmacodynamic biomarker studies of TRC105 anti-endoglin (CD105) antibody revealed anti-angiogenic activity associated with CD105 depletion. , 2016, , .		0
467	Abstract 1406: Analysis of immune responses as a consequence of androgen deprivation therapy in patients with biochemical progression of prostate cancer. , 2016, , .		0
468	Abstract LB-059: Neoadjuvant immunotherapy with androgen deprivation therapy (ADT) prior to radiation in prostate cancer: Impact on multiparametric prostate MRI and immune responses. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
469	Abstract CT080: Pharmacokinetic and pharmacodynamic analysis of M7824, a dual anti-PD-L1 and TGF β 2 TRAP molecule, in the first-in-human phase I dose escalation study. , 2017, , .		0
470	Abstract CT058: A phase 2 open-label study to evaluate the efficacy and safety of VT-464 in patients with androgen receptor positive triple-negative breast cancer patients, and men with ER positive breast cancer. , 2017, , .		0
471	Validation of a software-based clinical trial matching platform for oncology using comprehensive clinical information.. Journal of Clinical Oncology, 2018, 36, e18589-e18589.	0.8	0
472	Phase 1b results of avelumab in patients (pts) with previously treated metastatic melanoma enrolled in the JAVELIN Solid Tumor trial, including updated subgroup analyses.. Journal of Clinical Oncology, 2018, 36, e21531-e21531.	0.8	0
473	Abstract 3671: Phenotypic heterogeneity within prostate cancer bone metastases measured by 18F-DCFC PET/CT and 18F-NaF PET/CT. , 2018, , .		0
474	Abstract IA24: Making immunotherapy work in prostate cancer. , 2018, , .		0
475	Clinical efficacy of abiraterone and enzalutamide metastatic castration sensitive prostate cancer patients who progressed rapidly on docetaxel with a genomic analysis.. Journal of Clinical Oncology, 2019, 37, e16536-e16536.	0.8	0
476	Phase I trial of a modified vaccinia ankara (MVA) priming vaccine followed by a fowlpox virus (FPV) boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 2640-2640.	0.8	0
477	A tale of lineage plasticity: Intense neoadjuvant testosterone lowering therapy in localized prostate cancer (PCa) harboring high-risk genomic signatures.. Journal of Clinical Oncology, 2020, 38, 368-368.	0.8	0
478	Evaluating biomarkers in metastatic castration-resistant prostate cancer patients treated with enzalutamide: PSA, circulating tumor cell counts, AR-V7 status and radiographic progression.. Journal of Clinical Oncology, 2020, 38, e17569-e17569.	0.8	0
479	Spatial analysis of tumor immune microenvironment (TIME) in patients treated with Bintrafusp alfa.. Journal of Clinical Oncology, 2020, 38, 3070-3070.	0.8	0
480	Bicalutamide with or without metformin for biochemical recurrence in prostate cancer patients (BIMET-1).. Journal of Clinical Oncology, 2020, 38, 85-85.	0.8	0
481	The effect of deep AR suppression with enzalutamide or apalutamide on endogenous glucocorticoids: Implications for adverse effects and development of combination therapies.. Journal of Clinical Oncology, 2020, 38, 17-17.	0.8	0
482	SUN-739 Next Generation AR Antagonists Increase Systemic Active Glucocorticoid Exposure by Altering Glucocorticoid Metabolism. Journal of the Endocrine Society, 2020, 4, .	0.1	0
483	375â€¦Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa. , 2020, , .		0
484	296â€¦Immune correlates of clinical response to Avelumab in patients with advanced thymic epithelial tumors. , 2020, , .		0
485	265â€¦Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort. , 2020, , .		0
486	Celebrating a decade of the<i>Journal for ImmunoTherapy of Cancer</i>. , 2022, 10, e005207.		0